Company profile
Proteotype Diagnostics Ltd is a UK company with status active founded in 2019 based in East of England.
Financial period: 1 Nov 2023 to 31 Oct 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
RESOLUTIONS | Transaction WURBMkVVUzFhZGlxemtjeA | Paper/PDF filed
Published 26 Aug 2024 06:36
Company registered at Companies House
1 Dec 2024 to 30 Nov 2025
Detecting cancer earlier improves patient outcomes and reduces the burden of cancer on patients, their families, healthcare systems, and the economy. Proteotype is a startup company whose mission is to detect cancer earlier. Proteotype is developing the Enlighten (Registered Trademark) test, a groundbreaking test that can detect cancer at its earliest sta...
1 May 2024 to 31 Oct 2024
Cancer Research UK now estimates that 1 in 2 of us will develop cancer within our lifetime. In addition to being a significant personal concern from the patient perspective, cancer is also a major public healthcare challenge for single payor healthcare systems like the NHS. Cancer can be treated more effectively when detected early. More treatment options...
1 Dec 2023 to 31 Mar 2026
The NHS Long Term Plan on cancer endeavours to enable 55,000 more people to survive their cancer diagnosis by 5 years or more by 2028\. In recent years, targeted therapies have been improving survival for cancer patients compared to chemotherapy. While chemotherapy creates a generally hostile environment for cancer (and healthy) cells, targeted therapies ...
